PBS updates

Dupixent (Dupilumab)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes · INJECTION · PBS code 14977G

AUTHORITY_REQUIRED

What it costs

AU$1609.86 PBS-determined price per 2 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2025-09-01.
  • • Repeats: 0.
  • • PBS program: HS.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Uncontrolled severe asthma


Initial treatment - Initial 1 (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS-subsidised biological medicine therapy), Initial treatment - Initial 2 (Change of treatment), Continuing treatment, or transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements - Balance of Supply in a patient aged 6 to 12 years


Patient must have received insufficient therapy with this drug for this condition under the Initial treatment - Initial 1 (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS-subsidised biological medicine therapy) restriction to complete 32 weeks of treatment; or

Patient must have received insufficient therapy with this drug for this condition under the Initial treatment - Initial 2 (Change of treatment) restriction to complete 32 weeks of treatment; or

Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks of treatment; or

Patient must have received insufficient therapy with this drug for this condition under the transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements restriction to complete 24 weeks of treatment; AND

The treatment must provide no more than the balance of up to 32 weeks treatment available under the Initial 1 and Initial 2 restriction; or

The treatment must provide no more than the balance of up to 24 weeks treatment available under the Continuing and transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements restriction; AND

Must be treated by a medical practitioner who is either a: (i) paediatric respiratory physician, (ii) clinical immunologist, (iii) allergist, (iv) paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician.

Sponsor: sanofi-aventis Australia Pty Ltd ABN 31 008 558 807

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.